PDS BIOTECHNOLOGY CORP.

PDS Biotechnology has secured up to 22.55 million USD in a private placement led by Nant Capital. The initial closing is expected to raise about 11.55 million USD through the sale of common shares or prepaid warrants at 0.2825 USD per unit; a further milestone-dependent closing of 11 million USD will be triggered upon filing an FDA protocol for a Phase 3 study of PDS0301. Nant Capital will have the right to appoint two board members, including Dr. Patrick Soon-Shiong, if it reaches an economic stake of at least 15%. The proceeds will be used to repay indebtedness, for working capital, to further develop clinical programs, and for research and administration; NantWorks also received a one-year exclusive negotiation right for a license to PDS0101. » Más en de.investing.com

Lars Boesgaard submitted his resignation as CFO effective September 12, 2026; his departure is not related to any disagreements over the company’s business operations. The board appointed Janetta Trochimiuk as acting head of accounting and CEO Dr. Frank Bedu-Addo as acting chief financial officer, both positions effective September 12, 2026. Trochimiuk will retain her current base salary and remain eligible under the existing equity incentive plan; no new equity awards were granted. At the annual general meeting, shareholders approved increasing the number of authorized common shares from 150 million to 300 million. » Más en de.investing.com

Shareholders of PDS Biotechnology approved an amendment to increase the authorized common shares from 150 million to 300 million; the vote was 19,904,111 in favor and 11,545,436 against. At the annual meeting, where roughly 56.6% of outstanding shares were represented, Kamil Ali-Jackson and Ilian Iliev were elected as Class B directors. Shareholders also ratified KPMG US LLP as the independent registered public accounting firm for fiscal 2026 and approved a non-binding, advisory say-on-pay vote. » Más en de.investing.com